Genetic polymorphisms and cervical cancer development: ATM G5557A and p53bp1 C1236G

Oliveira,S.; Ribeiro,J.; Sousa,H.; Pinto,D.; Baldaque,I.; Medeiros,R.

doi:10.3892/or.2011.1609

Genetic polymorphisms and cervical cancer development: ATM G5557A and p53bp1 C1236G

Authors:
- S. Oliveira
- J. Ribeiro
- H. Sousa
- D. Pinto
- I. Baldaque
- R. Medeiros
View Affiliations

Affiliations: Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Rua Dr António Bernardino Almeida, 4200-072 Porto, Portugal, Molecular Oncology Group, CI, Portuguese Institute of Oncology of Porto, FG, EPE, Rua Dr António Bernardino Almeida, 4200-072 Porto, Portugal
Published online on: December 22, 2011 https://doi.org/10.3892/or.2011.1609
Pages: 1188-1192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Persistent infections by high-risk types of human papillomavirus (HPV) have been established as the etiological agent of cervical cancer. The integration of the HPV genome into the host genome is a crucial step in cervical carcinogenesis, although, correct activation of DNA damage repair pathways will avoid the development of cancer. Recent data indicate that several polymorphisms of key regulators from the DNA damage repair pathway (i.e. 53BP1 and ATM) are associated with cancer development susceptibility. We have developed a hospital-based retrospective study considering 429 cervical specimens from women with different cervical lesions including invasive carcinoma. This study aimed to evaluate the role of the ATM D1853N (5557G>A) and 53bp1 D353E (1236C>G) polymorphisms in the development of cervical cancer, using TaqMan® SNP Genotyping Assays. Statistical analysis revealed that ATM 5557GG homozygous individuals (OR=1.94; p=0.044) are at increased risk of developing LSIL, while for the 53BP1 1236C>G polymorphism no association was found. Nevertheless, we observed a tendency for an increased risk of LSIL in 53BP1 1236C allele carriers (OR=1.63; p=0.069). Logistic regression adjusted for age revealed no significant differences from the non-adjusted analysis. This is the first study to evaluate the role of ATM G5557A and P53BP1 C1236G polymorphisms in cervical cancer susceptibility. This study reveals a possible trend of both polymorphisms for a genetic susceptibility pattern of cervical cancer development. Hence, our results may be of interest for future understanding of the progression of cervical cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. IARC Press; Lyon: 2008
2	Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 4:46–54. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sankaranarayanan R and Ferlay J: Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
4	Vousden KH: Human papillomaviruses and cervical carcinoma. Cancer Cells. 1:43–50. 1989.PubMed/NCBI
5	Vousden KH: Human papillomavirus oncoproteins. Semin Cancer Biol. 1:415–424. 1990.
6	zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 184:9–13. 1991.PubMed/NCBI
7	Munoz N, Bosch FX, de Sanjose S, et al: Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 2:423–431. 1993.PubMed/NCBI
8	Munoz N, Castellsague X, de Gonzalez AB and Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine. 24(Suppl 3): S1–S10. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bosch FX, Munoz N, de Sanjose S, et al: Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 2:415–422. 1993.PubMed/NCBI
10	Franco EL, Rohan TE and Villa LL: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 91:506–511. 1999. View Article : Google Scholar : PubMed/NCBI
11	Castellsague X, Bosch FX and Munoz N: Environmental co-factors in HPV carcinogenesis. Virus Res. 89:191–199. 2002. View Article : Google Scholar : PubMed/NCBI
12	Matos A, Moutinho J, Pinto D and Medeiros R: The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev. 14:485–491. 2005. View Article : Google Scholar : PubMed/NCBI
13	Medeiros R, Prazeres H, Pinto D, et al: Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. Eur J Cancer Prev. 14:467–471. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sanlioglu S, Benson P and Engelhardt JF: Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology. 268:68–78. 2000. View Article : Google Scholar
15	Dehart JL, Andersen JL, Zimmerman ES, et al: The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. J Virol. 79:1389–1396. 2005. View Article : Google Scholar : PubMed/NCBI
16	Skalka AM and Katz RA: Retroviral DNA integration and the DNA damage response. Cell Death Differ. 12(Suppl 1): S971–S978. 2005. View Article : Google Scholar
17	Pett M and Coleman N: Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 212:356–367. 2007. View Article : Google Scholar : PubMed/NCBI
18	Costa S, Pinto D, Pereira D, et al: DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat. 103:209–217. 2007. View Article : Google Scholar
19	Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF and Koonin EV: A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11:68–76. 1997.PubMed/NCBI
20	Meulmeester E, Pereg Y, Shiloh Y and Jochemsen AG: ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle. 4:1166–1170. 2005. View Article : Google Scholar : PubMed/NCBI
21	Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003. View Article : Google Scholar : PubMed/NCBI
22	Callebaut I and Mornon JP: From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 400:25–30. 1997. View Article : Google Scholar : PubMed/NCBI
23	Schultz LB, Chehab NH, Malikzay A and Halazonetis TD: p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol. 151:1381–1390. 2000. View Article : Google Scholar : PubMed/NCBI
24	Rappold I, Iwabuchi K, Date T and Chen J: Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 153:613–620. 2001. View Article : Google Scholar : PubMed/NCBI
25	Anderson L, Henderson C and Adachi Y: Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol Cell Biol. 21:1719–1729. 2001. View Article : Google Scholar : PubMed/NCBI
26	Mochan TA, Venere M, DiTullio RA Jr and Halazonetis TD: 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 63:8586–8591. 2003.PubMed/NCBI
27	Mochan TA, Venere M, DiTullio RA Jr and Halazonetis TD: 53BP1, an activator of ATM in response to DNA damage. DNA Repair (Amst). 3:945–952. 2004. View Article : Google Scholar : PubMed/NCBI
28	Khanna KK and Chenevix-Trench G: ATM and genome maintenance: defining its role in breast cancer susceptibility. J Mammary Gland Biol Neoplasia. 9:247–262. 2004. View Article : Google Scholar : PubMed/NCBI
29	Khanna KK, Lavin MF, Jackson SP and Mulhern TD: ATM, a central controller of cellular responses to DNA damage. Cell Death Differ. 8:1052–1065. 2001. View Article : Google Scholar : PubMed/NCBI
30	Gatti RA, Berkel I, Boder E, et al: Localization of an ataxia-telangiectasia gene to chromosome 11q22–23. Nature. 336:577–580. 1988.
31	Chen G and Lee EYHP: The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J Biol Chem. 271:33693–33697. 1996. View Article : Google Scholar : PubMed/NCBI
32	Uziel T, Savitsky K, Platzer M, et al: Genomic Organization of the ATM gene. Genomics. 33:317–320. 1996. View Article : Google Scholar : PubMed/NCBI
33	Lavin MF and Shiloh Y: The genetic defect in ataxia-telangiectasia. Annu Rev Immunol. 15:177–202. 1997. View Article : Google Scholar : PubMed/NCBI
34	Thorstenson YR, Roxas A, Kroiss R, et al: Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 63:3325–3333. 2003.PubMed/NCBI
35	Maillet P, Vaudan G, Chappuis P and Sappino A: PCR-mediated detection of a polymorphism in the ATM gene. Mol Cell Probes. 13:67–69. 1999. View Article : Google Scholar : PubMed/NCBI
36	Thorstenson YR, Shen P, Tusher VG, et al: Global analysis of ATM polymorphism reveals significant functional constraint. Am J Hum Genet. 69:396–412. 2001. View Article : Google Scholar : PubMed/NCBI
37	Angele S, Falconer A, Edwards SM, et al: ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer. 91:783–787. 2004.PubMed/NCBI
38	Angele S, Romestaing P, Moullan N, et al: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 63:8717–8725. 2003.PubMed/NCBI
39	Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Nieminen P and Winqvist R: Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer. 116:69–72. 2005. View Article : Google Scholar : PubMed/NCBI
40	Tapia T, Sanchez A, Vallejos M, et al: ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences? Breast Cancer Res Treat. 107:281–288. 2008. View Article : Google Scholar : PubMed/NCBI
41	Maillet P, Chappuis PO, Vaudan G, et al: A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer. 88:928–931. 2000. View Article : Google Scholar : PubMed/NCBI
42	Meier M, den Boer ML, Hall AG, et al: Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia. 19:1887–1895. 2005. View Article : Google Scholar
43	Ma H, Hu Z, Zhai X, et al: Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis. 27:766–771. 2006. View Article : Google Scholar : PubMed/NCBI
44	Frank B, Hemminki K, Bermejo JL, et al: TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res. 7:R502–R505. 2005. View Article : Google Scholar : PubMed/NCBI
45	Daniel R, Kao G, Taganov K, et al: Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc Natl Acad Sci USA. 100:4778–4783. 2003. View Article : Google Scholar : PubMed/NCBI
46	Iwabuchi K, Basu BP, Kysela B, et al: Potential role for 53BP1 in DNA end-joining repair through direct interaction with DNA. J Biol Chem. 278:36487–36495. 2003. View Article : Google Scholar : PubMed/NCBI
47	Derbyshire DJ, Basu BP, Serpell LC, et al: Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J. 21:3863–3872. 2002. View Article : Google Scholar : PubMed/NCBI
48	Medeiros R, Morais A, Vasconcelos A, et al: The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet. 47:413–418. 2002. View Article : Google Scholar : PubMed/NCBI
49	Pinto D, Vasconcelos A, Costa S, et al: HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev. 13:177–181. 2004. View Article : Google Scholar : PubMed/NCBI
50	Cardoso CS, Araujo HC, Cruz E, et al: Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: Linkage to cervical cancer. Biochem Biophys Res Commun. 341:232–238. 2006. View Article : Google Scholar : PubMed/NCBI
51	Santos AM, Sousa H, Catarino R, et al: TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet. 159:143–147. 2005. View Article : Google Scholar : PubMed/NCBI
52	Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R and Dinis-Ribeiro M: COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol. 22:607–613. 2010. View Article : Google Scholar : PubMed/NCBI
53	Sousa H, Pando M, Breda E, Catarino R and Medeiros R: Role of the MDM2 SNP309 polymorphism in the initiation and early age of onset of nasopharyngeal carcinoma. Mol Carcinog. 50:73–79. 2011. View Article : Google Scholar : PubMed/NCBI
54	Sousa H, Breda E, Santos AM, Catarino R, Pinto D and Medeiros R: Genetic risk markers for nasopharyngeal carcinoma in Portugal: tumor necrosis factor alpha -308G>A polymorphism. DNA Cell Biol. 30:99–103. 2011. View Article : Google Scholar : PubMed/NCBI